To achieve this goal, Adeno-associated virus (AAV), which was approved as the gene therapy carrier for the treatment of lipoprotein lipase deficiency (Glybera) in 2012 and for the treatment of inherited vision loss (Luxturna) in 2017 [47, 48], can be used to deliver the wild-type full-length NR2E3 into cancer cells. This evidence concerns the gene NR2E3 and familial lipoprotein lipase deficiency.